NASDAQ:CDTX - Cidara Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.75
  • Forecasted Upside: 344.08 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$1.52
▲ +0.07 (4.83%)

This chart shows the closing price for CDTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cidara Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDTX

Analyst Price Target is $6.75
▲ +344.08% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cidara Therapeutics in the last 3 months. The average price target is $6.75, with a high forecast of $8.00 and a low forecast of $6.00. The average price target represents a 344.08% upside from the last price of $1.52.

This chart shows the closing price for CDTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Cidara Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/12/2020
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2021

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/3/2021HC WainwrightInitiated CoverageBuy$6.00Medium
9/22/2021AegisLower Price TargetBuy$9.00 ➝ $8.00High
9/22/2021WBB SecuritiesUpgradeBuy ➝ Strong-Buy$6.25High
3/4/2021AegisInitiated CoverageBuy$9.00High
11/6/2020Maxim GroupReiterated RatingBuy$10.00High
8/26/2020CitigroupLower Price TargetBuy$6.00 ➝ $5.00High
8/14/2020Maxim GroupReiterated RatingBuy$10.00Medium
8/14/2020Needham & Company LLCInitiated CoverageBuy$6.00Medium
8/13/2020OppenheimerReiterated RatingBuy$6.00Low
5/21/2020Maxim GroupInitiated CoverageBuy$10.00Medium
5/14/2020Needham & Company LLCInitiated CoverageBuy$6.00Medium
3/10/2020Maxim GroupInitiated CoverageBuyLow
3/5/2020Needham & Company LLCLower Price TargetBuy$10.00 ➝ $6.00Medium
12/4/2019WBB SecuritiesUpgradeSpeculative Buy ➝ Buy$6.25Medium
9/4/2019BTIG ResearchReiterated RatingBuy$7.00High
9/3/2019WedbushUpgradeNeutral ➝ Outperform$2.00 ➝ $4.00High
8/12/2019Needham & Company LLCSet Price TargetBuy$10.00High
6/12/2019Cantor FitzgeraldLower Price TargetOverweight ➝ Reduce$15.00 ➝ $8.00Low
6/5/2019OppenheimerInitiated CoverageOutperform$6.00High
5/17/2019WedbushDowngradeOutperform ➝ Neutral$2.00High
4/15/2019Cantor FitzgeraldReiterated RatingBuy$15.00Medium
3/1/2019WedbushLower Price TargetOutperform ➝ Outperform$12.00 ➝ $7.00Low
9/4/2018Cantor FitzgeraldSet Price TargetBuy$15.00Medium
8/9/2018Needham & Company LLCSet Price TargetBuy$14.00High
8/8/2018Cantor FitzgeraldReiterated RatingBuy$15.00High
7/25/2018CitigroupInitiated CoverageBuy$8.00Low
5/23/2018WBB SecuritiesUpgradeHold ➝ BuyMedium
5/10/2018Cantor FitzgeraldSet Price TargetBuy$15.00Medium
3/19/2018Cantor FitzgeraldSet Price TargetBuy$15.00Low
3/8/2018Cantor FitzgeraldSet Price TargetBuy$15.00Low
2/27/2018Cantor FitzgeraldSet Price TargetBuy$15.00High
1/19/2018Cantor FitzgeraldSet Price TargetBuy$15.00Low
11/28/2017Cantor FitzgeraldSet Price TargetBuy$15.00High
11/9/2017HC WainwrightBoost Price TargetBuy$14.00 ➝ $16.00N/A
9/26/2017Cantor FitzgeraldReiterated RatingBuy$15.00Low
8/11/2017Cantor FitzgeraldReiterated RatingOverweightHigh
8/11/2017WBB SecuritiesUpgradeSell ➝ HoldLow
8/10/2017Cantor FitzgeraldSet Price TargetBuy$15.00Low
6/26/2017Cantor FitzgeraldInitiated CoverageOverweight$15.00 ➝ $7.00High
6/24/2017Cantor FitzgeraldSet Price TargetBuy$15.00High
6/5/2017Cantor FitzgeraldSet Price TargetBuy$11.00Low
5/16/2017WedbushReiterated RatingOutperform$13.00Low
5/11/2017Cantor FitzgeraldSet Price TargetBuy$11.00Low
4/29/2017BTIG ResearchReiterated RatingBuy$15.00 ➝ $20.00Low
4/24/2017Cantor FitzgeraldReiterated RatingBuy$11.00High
4/20/2017Raymond JamesInitiated CoverageStrong-Buy$14.00High
4/17/2017HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $14.00Medium
4/12/2017LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$11.25Low
4/10/2017WedbushReiterated RatingOutperform ➝ Outperform$13.00Low
4/10/2017Needham & Company LLCReiterated RatingBuy$10.00Medium
4/7/2017Cantor FitzgeraldReiterated RatingBuyLow
3/24/2017Jefferies Financial GroupReiterated RatingBuy$15.00High
3/16/2017Needham & Company LLCReiterated RatingBuy$10.00Low
3/16/2017WedbushReiterated RatingOutperform$13.00Low
3/16/2017Cantor FitzgeraldReiterated RatingBuy$9.00High
2/22/2017HC WainwrightReiterated RatingBuy ➝ Buy$25.00 ➝ $18.00N/A
2/22/2017WBB SecuritiesUpgradeSell ➝ Hold$7.25N/A
2/21/2017Needham & Company LLCLower Price TargetBuy$20.00 ➝ $10.00N/A
2/21/2017WedbushReiterated RatingOutperform$13.00 ➝ $22.00N/A
1/11/2017Cantor FitzgeraldReiterated RatingBuy$20.00N/A
1/4/2017Cantor FitzgeraldSet Price TargetBuy$20.00N/A
1/4/2017BTIG ResearchReiterated RatingPositive$24.00N/A
12/21/2016SVB LeerinkInitiated CoverageOutperform$17.00N/A
12/19/2016HC WainwrightInitiated CoverageBuy$25.00N/A
(Data available from 12/4/2016 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/7/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/6/2021
  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/5/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/5/2021
  • 3 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/4/2021
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/4/2021

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Cidara Therapeutics logo
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $1.52
Low: $1.48
High: $1.64

50 Day Range

MA: $1.67
Low: $1.40
High: $2.35

52 Week Range

Now: $1.52
Low: $1.31
High: $3.15

Volume

1,178,144 shs

Average Volume

708,694 shs

Market Capitalization

$101.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Cidara Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Cidara Therapeutics in the last year: Aegis, HC Wainwright, WBB Securities, and Zacks Investment Research.
View the latest analyst ratings for CDTX.

What is the current price target for Cidara Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Cidara Therapeutics in the last year. Their average twelve-month price target is $6.75, suggesting a possible upside of 344.1%. Aegis has the highest price target set, predicting CDTX will reach $8.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for Cidara Therapeutics in the next year.
View the latest price targets for CDTX.

What is the current consensus analyst rating for Cidara Therapeutics?

Cidara Therapeutics currently has 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CDTX will outperform the market and that investors should add to their positions of Cidara Therapeutics.
View the latest ratings for CDTX.

What other companies compete with Cidara Therapeutics?

How do I contact Cidara Therapeutics' investor relations team?

Cidara Therapeutics' physical mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 752-6170 and its investor relations email address is [email protected] The official website for Cidara Therapeutics is www.cidara.com.